Venture Capital |
|
|
Astellas Venture Capital: Aim Big The foundation of every business, other than its product, is money. Earning money these days is as hard as finding one. Apart from a competitive market, a worldwide economic recession is also looming ahead. Venture capitalists have also become more cautious since losing from the dotcom bubble burst. Fortunately there are still venture capitalists willing to take on start up companies. Science and technology has been a great interest for private equity firms. They prove positive returns in the long run as demands of a fast pace world continue. In the world of biotechnology, Astellas Venture Management is one of the sources of venture capital funds. The company focuses on start up biotechnology companies. Its investment portfolio includes public companies such as Adherex Technologies, Memory Pharmaceuticals, and EPIX Pharmaceuticals. Private companies under them include F2G Ltd, FASgen, Inc., TaiGen Biotechnology Co., Ltd., and Alba Therapeutics Corporation. Astellas established a branch in the America in 2006. The headquarters were located at Los Altos, California. Astellas and biotech Most venture capitalists invest in high technology businesses. Most of them prefer companies that apply innovative technology to their product or services. They invest large amounts of capital to start up businesses that have a lot of growth potential in science, research and development. One of these private equity firms is Astellas Venture Management. Astellas was originally founded in Tokyo Japan. The company was formed after Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. merged. Both of these companies have already been investing in biotechnology companies in Japan before Astellas was formed. Astellas is now managing funds of clients from Yamanouchi and Fujisawa, including new limited partnerships. The focus of AVM is to find companies that have innovative technology and assist its growth by using its experience and network in the field of biotechnology. They offer investments for companies that have the potential to become leaders in the global market. They prefer emerging companies that are developing pharmaceutical seeds and new drug platforms. AVM is obviously a big firm. They have a comprehensive resource available to their clients from personnel networks to marketing operations. Apart from investments it also provides companies with scientific and technical proficiency, experience in drug development, marketing knowledge and long-term perspective. This is a big opportunity for those companies who want to have rapid growth and success. For those companies with a very ambitious management team this will be good partnership for them. AVM caters to no less than large markets that span globally not just locally. Their parent company called Astellas Pharma Inc. is one of the top pharmaceutical companies. This gives them the edge when it comes to experience. They are a cut above the rest when it comes to disease areas such as Immunology and Urology. The form is interested in the fields of Cancer, Pain, Diabetes and metabolic diseases. Having a pharmaceutical company is both good for entrepreneurs and investors. One of areas that are cannot be touched by recession is health care and medical services. Although being responsible for the well being of many people is a challenge it can also be rewarding. If you wish to delve in to a more competitive atmosphere and target a large market then you can go AVM, provided that you do have the scientific capabilities to back it up. |
|
| Venture Capital Recommended Products | |
| |
| Venture Capital Related Videos | |
| Venture Capital News | |
Venture capital poured into Utah in 2011Venture capital poured into Utah in 2011 By Steven Oberbeck The Salt Lake Tribune Published Jan 27, 2012 08:28AM MDT Venture capitalists stepped up their investments in Utah during the final quarter of 2011 in what is viewed as a positive sign of how investors see the future of the state’s economy and the companies based here. During the fourth quarter of 2011, venture capitalists invested ... Read more...Venture capital industry increasingly a world of haves and have-notsLong-predicted shakeout could mean fewer firms to fund startups Read more...Venture capital's quiet revolutionMany firms are just hanging on until the markets become more receptive to IPOs and they can cash in. Read more...Cebu needs venture capitalALTHOUGH Cebu is already blessed with inherent advantages, it needs to develop the venture capital (VC) market to be recognized as a mature IT-BPO destination, an industry stakeholder said. Read more...Venture capital firms that invest in biotech are particularly hard-hit by funding downturn.'Limited partners' are wary of investing given FDA's long process for approving new drugs. Read more... |
LINKS
Please visit Automatic Backlinks to start earning free backlinks
Copyright 2012 Venture-capital.ultrahitsboom.com. All Rights Reserved.
